Article info

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB
Free
  1. Correspondence to Dr Dick Menzies, Montreal Chest Institute, 3650 St-Urbain, Room K1.24, Montreal, Quebec, Canada H2X 2P4; dick.menzies{at}mcgill.ca
View Full Text

Citation

Aspler A, Long R, Trajman A, et al
Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Publication history

  • Received August 7, 2009
  • Accepted March 26, 2010
  • First published July 13, 2010.
Online issue publication 
July 13, 2010
  • Web Only Data thx.2009.125054

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.